Galapagos (NASDAQ:GLPG) Trading Up 3.7%

Shares of Galapagos NV (NASDAQ:GLPG) traded up 3.7% during mid-day trading on Tuesday . The stock traded as high as $29.54 and last traded at $29.43. 132,275 shares changed hands during trading, an increase of 2% from the average session volume of 129,142 shares. The stock had previously closed at $28.39.

Analysts Set New Price Targets

Separately, Raymond James downgraded shares of Galapagos from an “outperform” rating to a “market perform” rating in a research note on Friday, August 2nd.

Galapagos Price Performance

The company has a 50-day simple moving average of $25.88 and a two-hundred day simple moving average of $29.50.

Institutional Investors Weigh In On Galapagos

Several hedge funds have recently bought and sold shares of the stock. Quadrant Capital Group LLC lifted its position in Galapagos by 18.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,706 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 261 shares during the period. Headlands Technologies LLC lifted its stake in Galapagos by 56.7% in the 2nd quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 446 shares in the last quarter. Rhumbline Advisers increased its position in Galapagos by 21.6% in the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 814 shares during the last quarter. Signaturefd LLC lifted its position in Galapagos by 78.6% during the fourth quarter. Signaturefd LLC now owns 1,970 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 867 shares during the last quarter. Finally, GAMMA Investing LLC purchased a new position in shares of Galapagos in the 4th quarter worth $44,000. 32.46% of the stock is currently owned by institutional investors.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.